Travere Therapeutics
Partnership 2022 to present
2022 Expansion of Rare Disease Nephrology sales force to launch Sparsentan which is a treatment for patients with IgAN.
Placed 6 Zone Business Directors, 56 Clinical Account Managers (CAM’s), 1 Area Director of Medical Science Liaisons, and 7 Sr. Medical Science Liaisons.
2025 Expansion of Rare Disease FSGS. Placed 2 Sr Business Directors, 6 ZBD’s, 12 Clinical Account Managers, 1 Director, RKD Educator, 6 Thought Leader Liaisons, 6 Access Reimbursement Managers, 6 Strategic Account Managers, 6 Nurse Educators, and 2 Digital Medical Science Liaisons.
Primary focus isRare DiseaseinNephrology/Kidney.